Avances en uro-oncología «OncoForum»: lo mejor de 2013 |
| |
| Institution: | 1. Servicio de Urología, Hospital Universitario de Salamanca, Salamanca, España;2. Servicio de Urología, Hospital Clínic, Barcelona, España;3. Servicio de Urología, Hospital Ramón y Cajal, Madrid, España;4. Servicio de Urología, Hospital Virgen de las Nieves, Granada, España;1. Servicio de Urología, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, España;2. Servicio de Urología, Fundación Instituto Valenciano de Oncología, Valencia, España;3. Servicio de Radiodiagnóstico, Fundación Instituto Valenciano de Oncología, Valencia, España;4. Departamento de Matemática Aplicada, Universidad de Almería, Almería, España;1. Servicio de Anestesiología y Reanimación, Hospital Universitario Infanta Leonor, Madrid, España;2. Department of Anesthesia, Blekinge County Council Hospital, Karlskrona, Suecia;1. Dokuz Eylul University School of Medicine, Department of Urology, Izmir, Turquía;2. Dokuz Eylul University School of Medicine, Department of Pathology, Izmir, Turquía;3. Hacettepe University School of Medicine, Department of Public Health, Ankara, Turquía;1. Servicio de Neumología, Complejo Hospitalario Universitario de Albacete. Director Comité SEPAR Jóvenes, Albacete, España;2. Servicio de Neumología, IIS-Fundación Jiménez Díaz Quirón Salud, UAM, Madrid, España;3. CIBERES (Centro de Investigaciones Biomédica en Red de Enfermedades Respiratorias), España;4. Institut Respiratori, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, España |
| |
| Abstract: | ObjectiveTo present the new findings in oncologic urology with impact on clinical practice which were displayed at 2013 major annual meetings (EAU, ESTRO, AUA, ASCO and ASTRO).MethodsThe abstracts on prostate kidney, bladder and upper tract urothelial cancer with the highest scores by the OncoForum committee, presented in 1013 Congresses are included in this paper.Resultsthe following messages were considered as important by the OncoUrology Forum committee. In renal tumors T1a, comorbidities should be evaluated by its impact on overall and specific cancer survival, especially in men over 65. In metastatic renal tumors, the benefit of Everolimus vs. Sunitinib has not been demonstrated. Patients with non-muscle invasive bladder cancer of high risk, with three or more risk factors, should be considered for radical cystectomy. The ERSPC study’ data demonstrate the benefit of the systematic screening in prostate cancer. In metastatic disease, the results of the Ra-223 and enzalutamide studies show benefit in pain control and overall survival in metastatic disease.ConclusionsLocalized renal and non-muscle invasive bladder of high-risk tumors, should be assessed according to comorbidities or oncologic risk factors, to determinate the adequate treatment options. New data from metastatic prostate cancer clinical trials have shown promising results in the control of the disease |
| |
| Keywords: | Prostate cancer Bladder cancer Kidney cancer Upper tract urothelial cancer |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
